



**Additional file 1.** Distribution of Hb values during the follow-up among incident ESA users, stratified by indication for use: a) CKD; b) Cancer

a) CKD



b) Cancer



Incident ESA users starting the treatment at baseline Hb  $\geq 11$  g/dL were excluded